Funding for this research was provided by:
Leibniz-Institut für Präventionsforschung und Epidemiologie – BIPS GmbH
Received: 27 July 2021
Accepted: 25 January 2022
First Online: 2 February 2022
: In Germany, the utilisation of health insurance data for scientific research is regulated by the Code of Social Law. All involved health insurance providers as well as the German Federal Office for Social Security and the Senator for Health, Women and Consumer Protection in Bremen as their responsible authorities approved the use of GePaRD data for this study. Informed consent for studies based on claims data is required by law unless obtaining consent appears unacceptable and would bias results, which was the case in this study. According to the Ethics Committee of the University of Bremen studies based on GePaRD are exempt from institutional review board review. The study was performed according to the institutional guidelines of the Leibniz Institute for Prevention Research and Epidemiology – BIPS. All data was analyzed anonymously and the authors did not have access to identifying information.
: Not applicable
: MH, SS and UH are working at an independent, non-profit research institute, the Leibniz Institute for Prevention Research and Epidemiology – BIPS. Unrelated to this study, BIPS occasionally conducts studies financed by the pharmaceutical industry. Almost exclusively, these are post-authorization safety studies (PASS) requested by health authorities. The design and conduct of these studies as well as the interpretation and publication are not influenced by the pharmaceutical industry. The study presented was not funded by the pharmaceutical industry and was performed in line with the ENCePP Code of Conduct. FH has no conflicts of interest to disclose.